Compare KRUS & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | VOGX |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.1M | 482.8M |
| IPO Year | 2019 | 2026 |
| Metric | KRUS | VOGX |
|---|---|---|
| Price | $23.20 | $12.72 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $43.86 | N/A |
| AVG Volume (30 Days) | ★ 297.5K | 73.8K |
| Earning Date | 01-06-2027 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $328,276,000.00 | N/A |
| Revenue This Year | $15.09 | N/A |
| Revenue Next Year | $17.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.10 | N/A |
| 52 Week Low | $23.47 | $12.61 |
| 52 Week High | $80.84 | $38.41 |
| Indicator | KRUS | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 28.55 | 33.92 |
| Support Level | N/A | N/A |
| Resistance Level | $59.30 | $22.10 |
| Average True Range (ATR) | 2.18 | 2.36 |
| MACD | -0.66 | -0.60 |
| Stochastic Oscillator | 0.03 | 12.88 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.